Final NICE yes gives expensive Soliris market access
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has granted Alexion's Soliris (eculizumab) a yes in final guidance, opening the door to the market for the expensive rare disease treatment.